Ser405
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.4
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser405  -  CK1E (human)

Site Information
EVsRIPAsQtsVPFD   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 449794

In vivo Characterization
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling ( 17 , 18 ) , mass spectrometry ( 1 , 2 , 3 , 4 , 6 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 ) , mutation of modification site ( 17 , 18 ) , phosphopeptide mapping ( 17 )
Disease tissue studied:
breast cancer ( 3 ) , breast ductal carcinoma ( 3 ) , HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, surrounding tissue ( 1 ) , breast cancer, triple negative ( 1 ) , neuroblastoma ( 17 ) , melanoma skin cancer ( 2 )
Relevant cell line - cell type - tissue:
'muscle, skeletal' ( 8 ) , 293 (epithelial) ( 18 ) , A498 (renal) ( 14 ) , breast ( 1 , 3 ) , HCT116 (intestinal) ( 15 ) , HeLa (cervical) ( 6 ) , HeLa S3 (cervical) ( 16 ) , HeLa_Meta (cervical) ( 13 ) , HeLa_Pro (cervical) ( 13 ) , HeLa_Telo (cervical) ( 13 ) , Jurkat (T lymphocyte) ( 4 , 9 , 10 , 11 , 12 ) , K562 (erythroid) ( 6 ) , MDA-MB-435S (breast cell) ( 15 ) , MV4-11 (macrophage) ( 15 ) , Neuro-2a (neuron) ( 17 ) , WM239A (melanocyte) ( 2 )

Upstream Regulation
Putative in vivo kinases:
CK1E (human) ( 18 )
Putative upstream phosphatases:
PPP2CA (human) ( 18 )
Treatments:
ciclosporin ( 17 ) , DHPG ( 17 ) , ischemia ( 3 )

Downstream Regulation
Effects of modification on CK1E:
enzymatic activity, inhibited ( 17 , 18 )

References 

1

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

2

Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615
25850435   Curated Info

3

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

4

Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7
23749302   Curated Info

5

Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21
23312004   Curated Info

6

Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71
23186163   Curated Info

7

Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25
22424773   Curated Info

8

Lundby A, et al. (2012) Quantitative maps of protein phosphorylation sites across 14 different rat organs and tissues. Nat Commun 3, 876
22673903   Curated Info

9

Guo A (2011) CST Curation Set: 11375; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q
Curated Info

10

Guo A (2011) CST Curation Set: 11376; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q
Curated Info

11

Guo A (2011) CST Curation Set: 11381; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q
Curated Info

12

Guo A (2011) CST Curation Set: 11115; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho(Ser/Thr) ATM/ATR Substrate Antibody (polyAB) Cat#: 3005, PTMScan(R) Phospho-ATM/ATR Substrate Motif (pS/pTQ) Immunoaffinity Beads Cat#: 1980
Curated Info

13

Dulla K, et al. (2010) Quantitative site-specific phosphorylation dynamics of human protein kinases during mitotic progression. Mol Cell Proteomics 9, 1167-81
20097925   Curated Info

14

Schreiber TB, et al. (2010) An integrated phosphoproteomics work flow reveals extensive network regulation in early lysophosphatidic acid signaling. Mol Cell Proteomics 9, 1047-62
20071362   Curated Info

15

Oppermann FS, et al. (2009) Large-scale proteomics analysis of the human kinome. Mol Cell Proteomics 8, 1751-64
19369195   Curated Info

16

Daub H, et al. (2008) Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle. Mol Cell 31, 438-48
18691976   Curated Info

17

Liu F, Virshup DM, Nairn AC, Greengard P (2002) Mechanism of regulation of casein kinase I activity by group I metabotropic glutamate receptors. J Biol Chem 277, 45393-9
12223474   Curated Info

18

Gietzen KF, Virshup DM (1999) Identification of inhibitory autophosphorylation sites in casein kinase I epsilon. J Biol Chem 274, 32063-70
10542239   Curated Info